Acute liver failure （ALF） is a life-threatening illness. The extracorporeal cell-based bioartiflcial liver （BAL） system could bridge liver transplantation and facilitate liver regeneration for ALF patients by providing met- abolic detoxification and synthetic functions. Previous BAL systems, based on hepatoma cells and non-human hepatocytes, achieved limited clinical advances, largely due to poor hepatic functions, cumbersome preparation or safety concerns of these cells. We previously generated human functional hepatocytes by lineage conversion （hiHeps）. Here, by improving functional maturity of hiHeps and producing hiHeps at clinical scales （3 billion cells）, we developed a hiHep-based BAL system （hiHep-BAL）. In a porcine ALF model, hiHep-BAL treatment restored liver functions, corrected blood levels of ammonia and bilirubin, and prolonged survival. Importantly, human albumin and a-l-antitrypsin were detectable in hiHep-BAL-treated ALF pigs. Moreover, hiHep-BAL treatment led to attenuated liver damage, resolved inflammation and enhanced liver regeneration. Our findings indicate a promising clinical application of the hiHep-BAL system.